Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer.
Rosati G, Addeo R, Aprile G, Avallone A, Bilancia D, Brugnatelli S, Buccafusca G, Carlomagno C, Cordio S, Delfanti S, Dell'Aquila E, Di Bisceglie M, Di Donato S, Di Stasi A, Germano D, Giuliani F, Granetto C, Latiano TP, Leo S, Tralongo P, Stroppolo ME, Venturini F, Bianco S. Rosati G, et al. Among authors: addeo r. Cancer Chemother Pharmacol. 2019 Nov;84(5):1089-1096. doi: 10.1007/s00280-019-03943-x. Epub 2019 Sep 6. Cancer Chemother Pharmacol. 2019. PMID: 31493178
Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.
Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Marra M, Abbruzzese A, Palmieri G, Budillon A, Grillone F, Venuta S, Tagliaferri P, Del Prete S. Caraglia M, et al. Among authors: addeo r. Cancer Chemother Pharmacol. 2006 Jan;57(1):34-9. doi: 10.1007/s00280-005-0001-z. Epub 2005 Nov 5. Cancer Chemother Pharmacol. 2006. PMID: 16010592 Clinical Trial.
Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R, Faiola V, Guarrasi R, Montella L, Vincenzi B, Capasso E, Cennamo G, Rotundo MS, Tagliaferri P, Caraglia M, Del Prete S. Addeo R, et al. Cancer Chemother Pharmacol. 2008 Jul;62(2):285-92. doi: 10.1007/s00280-007-0605-6. Epub 2007 Oct 9. Cancer Chemother Pharmacol. 2008. PMID: 17922275 Clinical Trial.
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D'Agostino A, Faiola V, Addeo R. Prete SD, et al. Among authors: addeo r. Cancer Chemother Pharmacol. 2010 Oct;66(5):837-44. doi: 10.1007/s00280-009-1226-z. Epub 2009 Dec 30. Cancer Chemother Pharmacol. 2010. PMID: 20041325 Clinical Trial.
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.
Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G. Vincenzi B, et al. Among authors: addeo r. Ann Oncol. 2011 May;22(5):1141-1146. doi: 10.1093/annonc/mdq550. Epub 2010 Nov 29. Ann Oncol. 2011. PMID: 21115601 Free article.
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.
Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Bertolini F, Petrelli F, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G. Santini D, et al. Among authors: addeo r. Ann Oncol. 2012 Aug;23(8):2072-2077. doi: 10.1093/annonc/mdr572. Epub 2012 Jan 4. Ann Oncol. 2012. PMID: 22219016 Free article.
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G. Santini D, et al. Among authors: addeo r. Ann Oncol. 2012 Sep;23(9):2313-2318. doi: 10.1093/annonc/mdr623. Epub 2012 Mar 5. Ann Oncol. 2012. PMID: 22396447 Free article. Clinical Trial.
134 results